The role of vitamin D in Alzheimer's disease: Possible genetic and cell signaling mechanisms

American Journal of Alzheimer's Disease and other Dementias

Volumn 28, Issue 2, 2013, Pages 126-136

  L'O'Ng, Khanh Vinh Quoc ^a   Nguyen, Lan Thi Hoàng ^a  

^a Vietnamese American Medical Research Foundation   (United States)

Author keywords

Alzheimer's disease; calcitriol; dementia; vitamin D

Indexed keywords

AMYLOID BETA PROTEIN; ANGIOGENIN; CALCITRIOL; CALCIUM SENSING RECEPTOR; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; COMPLEMENT FACTOR H; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYOXALASE; HEME OXYGENASE 1; INTERLEUKIN 10; MATRIX METALLOPROTEINASE; MICRORNA 125B; MICRORNA 146A; MICRORNA 155; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; VASCULOTROPIN; VITAMIN D RECEPTOR;

3' UNTRANSLATED REGION; ALZHEIMER DISEASE; AMNESIA; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DEVELOPMENT; COGNITIVE DEFECT; DISEASE ASSOCIATION; DRUG EFFECT; GLYCATION; HUMAN; LUPUS ERYTHEMATOSUS; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; VITAMIN SUPPLEMENTATION;

EID: 84876532197     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317512473196     Document Type: Article

References (176)

1. Buell JS, Dawson-Hughes B, Scott TM, et al. 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology. 2010 ; 74 (1). 18-26
2. Annweiler C, Rolland Y, Schott AM, Blain H, Vellas B, Beauchet O. Serum vitamin D deficiency as a predictor of incident non-Alzheimer dementias: a 7-year longitudinal study. Dement Geriatr Cogn Disord. 2011 ; 32 (4). 273-278
3. Annweiler C, Rolland Y, Schott AM, et al. Higher vitamin d dietary intake is associated with lower risk of Alzheimer's disease: A 7-year follow-up [published online April 13, 2012]. J Gerontol A Biol Sci Med Sci. 2012 ;:
4. Wilkins CH, Sheline YI, Roe CM, Birge SJ, Morris JC. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry. 2006 ; 14 (12). 1032-1040
5. Wilkins CH, Birge SJ, Sheline YI, Morris JC. Vitamin D deficiency is associated with worse cognitive performance and lower bone density in older African Americans. J Natl Med Assoc. 2009 ; 101 (4). 349-354
6. Evatt ML, DeLong MR, Khazai N, Triche S, Tangpricha V. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008 ; 65: 1348-1352
7. Sato Y, Asoh T, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in elderly women with Alzheimer's disease. Bone. 1998 ; 23 (6). 555-557
8. Wilkins CH, Sheline YI, Roe CM, Birge SJ, Morris JC. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry. 2006 ; 14 (12). 1032-1040
9. Oudshoorn C, Mattace-Raso FUS, van der Velde N, Colin EM, van der Cammen TJM. Higher serum vitamin D3 levels are associated with better cognitive test performance in patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2008 ; 25 (6). 539-543
10. Llewellyn DJ, Lang IA, Langa KM, Melzer D. Vitamin D and cognitive impairment in the elderly U.S. population. J Gerontol A Biol Sci Med Sci. 2011 ; 66 (1). 59-65
11. Taghizadeh M, Djazayery A, Salami M, Eshraghian MR, Zavareh SA. Vitamin-D-free regimen intensifies the spatial learning deficit in Alzheimer's disease. Int J Neurosci. 2011 ; 121 (1). 16-24
12. Landfield PW, Cadwallader-Neal L. Long-term treatment with calcitriol (1,25(OH)2 vit D3) retards a biomarker of hippocampal aging in rats. Neurobiol Aging. 1998 ; 19 (5). 469-77
13. Larsson B, Nemere I. Effect of growth and maturation on membrane-initiated actions of 1,25-dihydroxyvitamin D3-II: calcium transport, receptor kinetics, and signal transduction in intestine of female chickens. J Cell Biochem. 2003 ; 90 (5). 901-913
14. Lecanu L, Rammouz G, McCourty A, Sidahmed EK, Greeson J, Papadopoulos V. Caprospinol reduces amyloid deposits and improves cognitive function in a rat model of Alzheimer's disease. Neuroscience. 2010 ; 165 (2). 427-435
15. Tohda C, Urano T, Umezaki M, Nemere I, Kuboyama T. Diosgenin is an exogenous activator of 1,25D3-MARRS/Pdia3/ERp57 and improves Alzheimer's disease pathologies in 5XFAD mice. Sci Rep. 2012 ; 2: 535
16. Lu'o'ng KV, Nguyên LT. The beneficial role of vitamin D in Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2011 ; 26 (7). 511-520
17. Veenstra TD, Prüfer K, Koenigsberger C, Brimijoin SW, Grande JP, Kumar R.. 1,25-Dihydroxyvitamin D3 receptors in the central nervous system of the rat embryo. Brain Res. 1998 ; 804 (2). 193-205
18. Prüfer K, Veenstra TD, Jirikowski GF, Kumar R. Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the rat brain and spinal cord. J Chem Neuroanat. 1999 ; 16 (2). 135-145
19. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat. 2005 ; 29 (1). 21-30
20. Sutherland MK, Somerville MJ, Yoong LKK, Bergeron C, Haussler MR, Mclachlan DRC. Reduction of vitamin D hormone receptor mRNA levels in Alzheimer as compared to Huntington hippocampus: correlation with calbindin-28 k mRNA levels. Mol Brain Res. 1992 ; 13 (3). 239-250
21. Kuningas M, Mooijaart SP, Jolles J, Slagboom PE, Westendorp RG, van Heemst D. VDR gene variants associate with cognitive function and depressive symptoms in old age. Neurobiol Aging. 2009 ; 30 (3). 466-473
22. Beydoun MA, Ding EL, Beydoun HA, Tanaka T, Ferrucci L, Zonderman AB. Vitamin D receptor and megalin gene polymorphisms and their associations with longitudinal cognitive change in US adults. Am J Clin Nutr. 2012 ; 95 (1). 163-178
23. Lehmann DJ, Refsum H, Warden DR, Medway C, Wilcock GK, Smith AD. The vitamin D receptor gene is associated with Alzheimer's disease. Neurosci Lett. 2011 ; 504 (2). 79-82
24. Wang L, Hara K, Van Baaren JM, et al. Vitamin D receptor and Alzheimer's disease: a genetic and functional study. Neurobiol Aging. 2012 ; 33 (8). e1-1849
25. Gezen-Ak D, Dursun E, Bilgiç B, et al. Vitamin d receptor gene haplotype is associated with late-onset Alzheimer's disease. Tohoku J Exp Med. 2012 ; 228 (3). 189-196
26. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS One. 2008 ; 3 (9). e3148
27. Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun. 2009 ; 32 (3-4). 189-194
28. Lu LF, Liston A. MicroRNA in the immune system, microRNA as an immune system. Immunology. 2009 ; 127 (3). 291-298
29. Lukiw WJ, Zhao Y, Cui JG. An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem. 2008 ; 283 (46). 31315-31322
30. Cui JG, Li YY, Zhao Y, Bhattacharjee S, Lukiw WJ. Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease. J Biol Chem. 2010 ; 285 (50). 38951-38960
31. Pogue AI, Cui JG, Li YY, Zhao Y, Culicchia F, Lukiw WJ. Micro RNA-125b (miRNA-125b) function in astrogliosis and glial cell proliferation. Neurosci Lett. 2010 ; 476 (1). 18-22
32. Lukiw WJ, Alexandrov PN, Zhao Y, Hill JM, Bhattacharjee S. Spreading of Alzheimer's disease inflammatory signaling through soluble micro-RNA. Neuroreport. 2012 ; 23 (10). 621-626
33. Wang G, Tam LS, Kwan BC, et al. Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus. Clin Rheumatol. 2012 ; 31 (3). 435-440
34. Wang Y, Borchert ML, Deluca HF. Identification of the vitamin D receptor in various cells of the mouse kidney. Kidney Int. 2012 ; 81 (10). 993-1001
35. Jorde R, Svartberg J, Joakimsen RM, Coucheron DH. Plasma profile of microRNA after supplementation with high doses of vitamin D3 for 12 months. BMC Res Notes. 2012 ; 5: 245
36. Pan YZ, Gao W, Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos. 2009 ; 37 (10). 2112-2117
37. Komagata S, Nakajima M, Takagi S, Mohri T, Taniya T, Yokoi T. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol Pharmacol. 2009 ; 76 (4). 702-709
38. Mohri T, Nakajima M, Takagi S, Komagata S, Yokoi T. MicroRNA regulates human vitamin D receptor. Int J Cancer. 2009 ; 125: 1328-1333
39. Wang WL, Chatterjee N, Chittur SV, Welsh J, Tenniswood MP. Effects of 1α,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 ; 10: 58
40. Essa S, Denzer N, Mahlknecht U, et al. VDR microRNA expression and epigenetic silencing of vitamin D signaling in melanoma cells. J Steroid Biochem Mol Biol. 2010 ; 121 (1-2). 110-113
41. Zhang W, Wang LZ, Yu JT, Chi ZF, Tan L. Increased expressions of TLR2 and TLR4 on peripheral blood mononuclear cells from patients with Alzheimer's disease. J Neurol Sci. 2012 ; 315 (1-2). 67-71
42. Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. CD14 and toll-like receptors 2 and 4 are required for fibrillar Aβ-stimulated microglial activation. J Neurosci. 2009 ; 29 (38). 11982-11892
43. Jin JJ, Kim HD, Maxwell JA, Li L, Fukuchi K. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation. 2008 ; 5: 23
44. Liu S, Liu Y, Hao W, et al. TLR2 is a primary receptor for Alzheimer's amyloid β peptide to trigger neuroinflammatory activation. J Immunol. 2012 ; 188 (3). 1098-1107
45. Jana M, Palencia CA, Pahan K. Fibrillar amyloid-beta peptides activate microglia via TLR2: implications for Alzheimer's disease. J Immunol. 2008 ; 181 (10). 7254-7262
46. Vollmar P, Kullmann JS, Thilo B, et al. Active immunization with amyloid-beta 1-42 impairs memory performance through TLR2/4-dependent activation of the innate immune system. J Immunol. 2010 ; 185 (10). 6338-6347
47. Tang SC, Lathia JD, Selvaraj PK, et al. Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp Neurol. 2008 ; 213 (1). 114-121
48. Wang LZ, Tian Y, Yu JT, et al. Association between late-onset Alzheimer's disease and microsatellite polymorphisms in intron II of the human toll-like receptor 2 gene. Neurosci Lett. 2011 ; 489 (3). 164-167
49. Yu JT, Mou SM, Wang LZ, Mao CX, Tan L. Toll-like receptor 2 -196 to -174 del polymorphism influences the susceptibility of Han Chinese people to Alzheimer's disease. J Neuroinflammation. 2011 ; 8: 136
50. Wang LZ, Yu JT, Miao D, et al. Genetic association of TLR4/11367 polymorphism with late-onset Alzheimer's disease in a Han Chinese population. Brain Res. 2011 ; 1381: 202-207
51. Yu JT, Miao D, Cui WZ, et al. Common variants in toll-like receptor 4 confer susceptibility to Alzheimer's disease in a Han Chinese population. Curr Alzheimer Res. 2012 ; 9 (4). 458-466
52. Minoretti P, Gazzaruso C, Vito CD, et al. Effect of the functional toll-like receptor 4 Asp299Gly polymorphism on susceptibility to late-onset Alzheimer's disease. Neurosci Lett. 2006 ; 391 (3). 147-149
53. Song M, Jin J, Lim JE, et al. TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J Neuroinflammation. 2011 ; 8: 92
54. Soscia SJ, Kirby JE, Washicosky KJ, et al. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One. 2010 ; 5 (3). e9505
55. Ciornei CD, Tapper H, Bjartell A, Sternby NH, Bodelsson M. Human antimicrobial peptide LL-37 is present in atherosclerotic plaques and induces death of vascular smooth muscle cells: a laboratory study. BMC Cardiovasc Disord. 2006 ; 6: 49
56. Roth CL, Elfers CT, Figlewicz DP, et al. Vitamin D deficiency in obese rats exacerbates NAFLD and increases hepatic resistin and toll-like receptor activation. Hepatology. 2012 ; 55: 1103-1111
57. Sadeghi K, Wessner B, Laggner U, et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol. 2006 ; 36 (2). 361-370
58. Dickie L, Church L, Coulthard L, Mathews R, Emery P, McDermott M. Vitamin D3 downregulates intracellular toll-like receptor 9 expression and toll-like receptor 9-induced IL-6 production in human monocytes. Rheumatology. 2010 ; 49 (8). 1466-1471
59. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006 ; 311 (5768). 1770-1773
60. Yim S, Dhawan P, Ragunath C, Christakos S, Diamond G. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25- dihydroxyvitamin D3. J Cys Fibros. 2007 ; 6 (6). 403-410
61. Rivas-Santiago B, Hernandez-Pando R, Carranza C, et al. Expression of cathelicidin LL-37 during Mycobacterium tuberculosis infection in human alveolar macrophages, monocytes, neutrophils, and epithelial cells. Infect Immunity. 2008 ; 76 (3). 935-941
62. Schultheiss C, Blechert B, Gaertner FC, Drecoll E, Mueller J.. In vivo characterization of endothelial cell activation in a transgenic mouse model of Alzheimer's disease. Angiogenesis. 2006 ; 9: 59-65
63. Thirumangalakudi L, Samany PG, Owoso A, Wiskar B, Grammas P. Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. J Alzheimers Dis. 2006 ; 10: 111-118
64. Kalaria RN, Cohen DL, Premkumar DR, Nag S, LaManna JC, Lust WD. Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. Brain Res Mol Brain Res. 1998 ; 62 (1). 101-105
65. Tarkowski E, Issa R, Sjögren M, et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging. 2002 ; 23 (2). 237-243
66. Yang SP, Bae DG, Kang HJ, Gwag BJ, Gho YS, Chae CB. Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging. 2004 ; 25 (3). 283-290
67. Patel NS, Mathura VS, Bachmeier C, et al. Alzheimer's beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2. J Neurochem. 2010 ; 112 (1). 66-76
68. Del Bo R, Ghezzi S, Scarlato M, et al. Role of VEGF gene variability in longevity: a lesson from the Italian population. Neurobiol Aging. 2008 ; 29 (12). 1917-1922
69. Del Bo R, Scarlato M, Ghezzi S, et al. Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol. 2005 ; 57 (3). 373-380
70. Chiappelli M, Borroni B, Archetti S, et al. VEGF gene and phenotype relation with Alzheimer's disease and mild cognitive impairment. Rejuvenation Res. 2006 ; 9 (4). 485-493
71. Yuan Q, Zuo X, Jia J. Association between promoter polymorphisms of vascular endothelial growth factor gene and sporadic Alzheimer's disease among Northern Chinese Han. Neurosci Lett. 2009 ; 457 (3). 133-136
72. Smach MA, Charfeddine B, Othman LB, et al. -1154G/A and -2578C/A polymorphisms of the vascular endothelial growth factor gene in Tunisian Alzheimer patients in relation to beta-amyloid (1-42) and total tau protein. Neurosci Lett. 2010 ; 472 (2). 139-142
73. Mantell D, Owens P, Bundred N, Mawer E, Canfield A.. 1α,25- dihydroxyvitamin D3 inhibits angiogenesis in vitro and in vivo. Circ Res. 2000 ; 87 (3). 214-220
74. Gruber H, Hoelscher G, Ingram J, Chow Y, Loffler B, Hanley E.. 1α,25-dihydroxyvitamin D3 inhibits proliferation and decreases production of monocyte chemoattractant protein-1, thrombopoietin, VEGF, and angiogenin by human annulus cells in vitro. Spine. 2008 ; 33 (7). 755-765
75. Albert D, Scheef E, Wang S, et al. Calcitriol is a potent inhibitor of retinal neovascularization. Invest Ophthalmol Vis Sci. 2007 ; 48 (5). 2327-2334
76. Nakagawa K, Sasaki Y, Kato S, et al. 22-Oxa-1α,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis. 2005 ; 26 (6). 1044-1054
77. Ben-Shoshan M, Amir S, Dang D, Dang L, Weisman Y, Mabjeesh N.. 1α,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth pathway in human cancer cells. Mol Cancer Ther. 2007 ; 6 (4). 1433-1439
78. Moroianu J, Riordan JF. Identification of the nucleolar targeting signal of human angiogenin. Biochem Biophys Res Commun. 1994 ; 203 (3). 1765-1772
79. Kieran D, Sebastia J, Greenway MJ, et al. Control of motoneuron survival by angiogenin. J Neurosci. 2008 ; 28 (52). 14056-14061
80. Kim YN, Kim do H. Decreased serum angiogenin level in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2012 ; 38 (2). 116-120
81. Hooper LV, Stappenbeck TS, Hong CV, Gordon JI. Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat Immunol. 2003 ; 4 (3). 269-273
82. Lagishetty V, Misharin AV, Liu NQ, et al. Vitamin D deficiency in mice impairs colonic antibacterial activity and predisposes to colitis. Endocrinology. 2010 ; 151 (6). 2423-2432
83. Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl). 2005 ; 83 (11). 876-886
84. Chen F, Wollmer MA, Hoerndli F, et al. Role for glyoxalase I in Alzheimer's disease. Proc Natl Acad Sci U S A. 2004 ; 101 (20). 7687-7692
85. Kuhla B, Boeck K, Schmidt A, et al. Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains. Neurobiol Aging. 2007 ; 28 (1). 29-41
86. Shuvaev VV, Laffont I, Serot JM, Fujii J, Taniguchi N, Siest G. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol Aging. 2001 ; 22 (3). 397-402
87. Riviere S, Birlouez-Aragon I, Vellas B. Plasma protein glycation in Alzheimer's disease. Glycoconj J. 1998 ; 15: 1039-1042
88. Sasaki N, Toki S, Chowei H, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res. 2001 ; 888 (2). 256-262
89. Miller MC, Tavares R, Johanson CE, et al. Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res. 2008 ; 1230: 273-280
90. Lue LF, Walker DG, Brachova L, et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol. 2001 ; 171 (1). 29-45
91. Du Yan S, Zhu H, Fu J, et al. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A. 1997 ; 94 (10). 5296-5301
92. Li K, Dai D, Zhao B, et al. Association between the RAGE G82 S polymorphism and Alzheimer's disease. J Neural Transm. 2010 ; 117 (1). 97-104
93. Daborg J, von Otter M, Sjölander A, et al. Association of the RAGE G82 S polymorphism with Alzheimer's disease. J Neural Transm. 2010 ; 117 (7). 861-867
94. Wilson JS, Mruthinti S, Buccafusco JJ, et al. Anti-RAGE and Abeta immunoglobulin levels are related to dementia level and cognitive performance. J Gerontol A Biol Sci Med Sci. 2009 ; 64 (2). 264-271
95. Talmor-Barkan Y, Bernheim J, Green J, Benchetrit S, Rashid G.. Calcitriol counteracts endothelial cell pro-inflammatory processes in a chronic kidney disease-like environment. J Steroid Biochem Mol Biol. 2011 ; 124: 19-24
96. Talmor Y, Golan E, Benchetrit S, et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol. 2008 ; 294 (5). F1059 - F1064
97. Talmor Y, Bernheim J, Klein O, Green J, Rashid G.. Calcitriol blunts pro-atherosclerotic parameters through NFkappaB and p38 in vitro. Eur J Clin Invest. 2008 ; 38: 548-554
98. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev. 2001 ; 81 (1). 239-297
99. Magno AL, Ward BK, Ratajczak T. The calcium-sensing receptor: a molecular perspective. Endocr Rev. 2011 ; 32: 3-30
100. Yano S, Brown EM, Chattopadhyay N. Calcium-sensing receptor in the brain. Cell Calcium. 2004 ; 35 (3). 257-264
101. Braunewell K, Riederer P, Spilker C, Gundelfinger ED, Bogerts B, Bernstein HG.. Abnormal localization of two neuronal calcium sensor proteins, visinin-like proteins (vilips)-1 and -3, in neocortical brain areas of Alzheimer disease patients. Dement Geriatr Cogn Disord. 2001 ; 12 (2). 110-116
102. Schnurra I, Bernstein HG, Riederer P, Braunewell KH. The neuronal calcium sensor protein VILIP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer's disease and promotes cell death and tau phosphorylation in vitro: a link between calcium sensors and Alzheimer's disease?. Neurobiol Dis. 2001 ; 8 (5). 900-909
103. Ye C, Ho-Pao CL, Kanazirska M, et al. Amyloid-beta proteins activate Ca2+-permeable channels through calcium-sensing receptors. J Neurosci Res. 1997 ; 47 (5). 547-554
104. Chiarini A, Dal Pra I, Marconi M, Chakravarthy B, Whitfield JF, Armato U. Calcium-sensing receptor (CaSR) in human brain's pathophysiology: roles in late-onset Alzheimer's disease (LOAD). Curr Pharm Biotechnol. 2009 ; 10 (3). 317-326
105. Chattopadhyay N, Espinosa-Jeffrey A, Tfelt-Hansen J, et al. Calcium receptor expression and function in oligodendrocyte commitment and lineage progression: potential impact on reduced myelin basic protein in CaR-null mice. J Neurosci Res. 2008 ; 86 (10). 2159-2167
106. Conley YP, Mukherjee A, Kammerer C, et al. Evidence supporting a role for the calcium-sensing receptor in Alzheimer disease. Am J Med Genet B Neuropsychiatr Genet. 2009 ; 150B (5). 703-709
107. Brown AJ, Zhong M, Finch J, et al. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol. 1996 ; 270 (3 pt 2). F454 - F460
108. Canaff L, Hendy GN. Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem. 2002 ; 277 (33). 30337-3050
109. He YH, Song Y, Liao XL, et al. The calcium-sensing receptor affects fat accumulation via effects on antilipolytic pathways in adipose tissue of rats fed low-calcium diets. J Nutr. 2011 ; 141 (11). 1938-1946
110. Yao JJ, Bai S, Karnauskas AJ, Bushinsky DA, Favus MJ. Regulation of renal calcium receptor gene expression by 1,25-dihydroxyvitamin D3 in genetic hypercalciuric stone-forming rats. J Am Soc Nephrol. 2005 ; 16 (5). 1300-1308
111. Chakrabarty S, Wang H, Canaff L, Hendy GN, Appelman H, Varani J. Calcium sensing receptor in human colon carcinoma: interaction with Ca2+ and 1,25-dihydroxyvitamin D3. Cancer Res. 2005 ; 65: 493-498
112. Gezen-Ak D, Dursun E, Yilmazer S. The effects of vitamin D receptor silencing on the expression of LVSCC-A1C and LVSCC-A1D and the release of NGF in cortical neurons. PLoS One. 2011 ; 6 (3). e17553
113. Dursun E, Gezen-Ak D, Yilmazer S. A novel perspective for Alzheimer's disease: vitamin D receptor suppression by amyloid-β and preventing the amyloid-β induced alterations by vitamin D in cortical neurons. J Alzheimers Dis. 2011 ; 23 (2). 207-219
114. Fiala M, Porter V. Delineating Alzheimer's disease progression with MGAT3, a biomarker for improved prognosis and personalized therapy. Biomark Med. 2011 ; 5 (5). 645-647
115. Fiala M, Mahanian M, Rosenthal M, et al. MGAT3 mRNA: a biomarker for prognosis and therapy of Alzheimer's disease by vitamin D and curcuminoids. J Alzheimers Dis. 2011 ; 25 (1). 135-144
116. Masoumi A, Goldenson B, Ghirmai S, et al. 1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. J Alzheimers Dis. 2009 ; 17 (3). 703-717
117. Mizwicki MT, Menegaz D, Zhang J, et al. Genomic and nongenomic signaling induced by 1α,25(OH)2-vitamin D3 promotes the recovery of amyloid-β phagocytosis by Alzheimer's disease macrophages. J Alzheimers Dis. 2012 ; 29: 51-62
118. Lee V, Rekhi E, Hoh Kam J, Jeffery G. Vitamin D rejuvenates aging eyes by reducing inflammation, clearing amyloid beta and improving visual function. Neurobiol Aging. 2012 ; 33 (10). 2382-2389
119. Yu J, Gattoni-Celli M, Zhu H, et al. Vitamin D3-enriched diet correlates with a decrease of amyloid plaques in the brain of AβPP transgenic mice. J Alzheimers Dis. 2011 ; 25: 295-307
120. Ito S, Ohtsuki S, Nezu Y, Koitabashi Y, Murata S, Terasaki T.. 1α,25-Dihydroxyvitamin D3 enhances cerebral clearance of human amyloid-β peptide(1-40) from mouse brain across the blood-brain barrier. Fluids Barriers CNS. 2011 ; 8: 20
121. Speciale L, Calabrese E, Saresella M, et al. Lymphocyte subset patterns and cytokine production in Alzheimer's disease patients. Neurobiol Aging. 2007 ; 28 (8). 1163-1169
122. De Luigi A, Fragiacomo C, Lucca U, et al. Inflammatory markers in Alzheimer's disease and multi-infarct dementia. Mech Ageing Dev. 2001 ; 122 (16). 1985-1995
123. Kiyota T, Ingraham KL, Swan RJ, Jacobsen MT, Andrews SJ, Ikezu T. AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice. Gene Ther. 2012 ; 19 (7). 724-733
124. Ma SL, Tang NL, Lam LC, Chiu HF. The association between promoter polymorphism of the interleukin-10 gene and Alzheimer's disease. Neurobiol Aging. 2005 ; 26 (7). 1005-1010
125. Bagnoli S, Cellini E, Tedde A, et al. Association analysis of the paraoxonase-1 gene with Alzheimer's disease. Neurosci Lett. 2006 ; 408 (3). 199-202
126. Arosio B, Mastronardi L, Vergani C, Annoni G.. Intereleukin-10 promoter polymorphism in mild cognitive impairment and in its clinical evolution. Int J Alzheimers Dis. 2010 ; 2010: pii - 854527
127. Zhang Y, Zhang J, Tian C, et al. The -1082G/A polymorphism in IL-10 gene is associated with risk of Alzheimer's disease: a meta-analysis. J Neurol Sci. 2011 ; 303 (1-2). 133-138
128. Di Bona D, Rizzo C, Bonaventura G, Candore G, Caruso C. Association between interleukin-10 polymorphisms and Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis. 2012 ; 29 (4). 751-759
129. Spach KM, Nashold FE, Dittel BN, Hayes CE. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol. 2006 ; 177 (9). 6030-6037
130. Matilainen JM, Räsänen A, Gynther P, Väisänen S.. The genes encoding cytokines IL-2, IL-10 and IL-12B are primary 1alpha,25(OH)2D3 target genes. J Steroid Biochem Mol Biol. 2010 ; 121 (1-2). 142-145
131. Zittermann A, Dembinski J, Stehle P. Low vitamin D status is associated with low cord blood levels of the immunosuppressive cytokine interleukin-10. Pediatr Allergy Immunol. 2004 ; 15 (3). 242-246
132. Michel G, Gailis A, Jarzebska-Deussen B, Müschen A, Mirmohammadsadegh A. Ruzicka T. 1,25-(OH)2-vitamin D3 and calcipotriol induce IL-10 receptor gene expression in human epidermal cells. Inflamm Res. 1997 ; 46 (1). 32-34
133. Khoo AL, Joosten I, Michels M, et al. 1,25-Dihydroxyvitamin D3 inhibits proliferation but not the suppressive function of regulatory T cells in the absence of antigen-presenting cells. Immunology. 2011 ; 134 (4). 459-468
134. Thota C, Farmer T, Garfield RE, Menon R, Al-Hendy A. Vitamin D elicits anti-inflammatory response, inhibits contractile-associated proteins, and modulates toll-like receptors in human myometrial cells [published online September 25]. Reprod Sci. 2012 ;:
135. Leake A, Morris CM, Whateley J. Brain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease. Neurosci Lett. 2000 ; 291 (3). 201-203
136. Horstmann S, Budig L, Gardner H, et al. Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease. Int Psychogeriatr. 2010 ; 22 (6). 966-972
137. Yoshiyama Y, Asahina M, Hattori T. Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain. Acta Neuropathol. 2000 ; 99 (2). 91-95
138. Lorenzl S, Albers DS, Relkin N, et al. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int. 2003 ; 43 (3). 191-196
139. Asahina M, Yoshiyama Y, Hattori T. Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin Neuropathol. 2001 ; 20 (2). 60-63
140. Bruno MA, Mufson EJ, Wuu J, Cuello AC. Increased matrix metalloproteinase 9 activity in mild cognitive impairment. J Neuropathol Exp Neurol. 2009 ; 68 (12). 1309-1318
141. Deb S, Gottschall PE. Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J Neurochem. 1996 ; 66 (4). 1641-1647
142. Du H, Li P, Wang J, Qing X, Li W. The interaction of amyloid β and the receptor for advanced glycation endproducts induces matrix metalloproteinase-2 expression in brain endothelial cells. Cell Mol Neurobiol. 2012 ; 32: 141-147
143. Flex A, Gaetani E, Proia AS, et al. Analysis of functional polymorphisms of metalloproteinase genes in persons with vascular dementia and Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 2006 ; 61 (10). 1065-1069
144. Reitz C, van Rooij FJ, Soares HD, et al. Matrix metalloproteinase 3 haplotypes and plasma amyloid beta levels: the Rotterdam Study. Neurobiol Aging. 2010 ; 31 (4). 715-718
145. Helbecque N, Cottel D, Hermant X, Amouyel P. Impact of the matrix metalloproteinase MMP-3 on dementia. Neurobiol Aging. 2007 ; 28 (8). 1215-1220
146. Mizoguchi H, Takuma K, Fukuzaki E, et al. Matrix metalloprotease-9 inhibition improves amyloid beta-mediated cognitive impairment and neurotoxicity in mice. J Pharmacol Exp Ther. 2009 ; 331 (1). 14-22
147. Sundar I, Hwang J, Wu S, Sun J, Rahman I. Deletion of vitamin D receptor leads to premature emphysema/COPD by increased matrix metalloproteinase and lymphoid aggregates formation. Biochem Biophys Res Commun. 2011 ; 406 (1). 127-133
148. Timms PM, Mannan N, Hitman GA, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders?. Q J Med. 2002 ; 95 (12). 787-796
149. Dean DD, Schwartz Z, Schmitz J, et al. Vitamin D regulation of metalloproteinase activity in matrix vesicles. Connect Tissue Res. 1996 ; 35 (1-4). 331-336
150. Bahar-Shany K, Ravid A, Koren R. Upregulation of MMP-production by TNFalpha in keratinocytes and its attenuation by vitamin D. J Cell Physiol. 2010 ; 222 (3). 729-737
151. Lacraz S, Dayer J, Nicod L, Welgus H.. 1,25-dihydroxyvitamin D3 dissociates production of interstitial collagenase and 92-kDa gelatinase in human mononuclear phagocytes. J Biol Chem. 1994 ; 269 (9). 6485-6490
152. Nakagawa K, Sasaki Y, Kato S, Kubodera N. Okano T. 22-Oxa-1α,25- dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis. 2005 ; 26 (6). 1044-1054
153. Coussens A, Timms P. Boucher B, et al. 1α,25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infection. Immunology. 2009 ; 127 (4). 539-548
154. Anand S, Selvaraj P.. Effect of 1,25 dihydroxyvitamin D3 on matrix metalloproteinases MMP-7, MMP-9 and the inhibitor TIMP-1 in pulmonary tuberculosis. Clin Immunol. 2009 ; 133 (1). 126-131
155. Tetlow L, Woolley D. Expression of vitamin D receptors and matrix metalloproteinases in osteoarthritic cartilage and human articular chondrocytes in vitro. Osteoarthritis Cartilage. 2001 ; 9 (5). 423-431
156. Takahashi T, Morita K, Akagi R, Sassa S. Protective role of heme oxygenase-1 in renal ischemia. Antioxid Redox Signal. 2004 ; 6 (5). 867-877
157. Premkumar DR, Smith MA, Richey PL, et al. Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer's disease. J Neurochem. 1995 ; 65 (3). 1399-1402
158. Schipper HM. Glial HO-1 expression, iron deposition and oxidative stress in neurodegenerative diseases. Neurotox Res. 1999 ; 1 (1). 57-70
159. Song W, Su H, Song S, Paudel HK, Schipper HM. Over-expression of heme oxygenase-1 promotes oxidative mitochondrial damage in rat astroglia. J Cell Physiol. 2006 ; 206 (3). 655-663
160. Hui Y, Wang D, Li W, et al. Long-term overexpression of heme oxygenase 1 promotes tau aggregation in mouse brain by inducing tau phosphorylation. J Alzheimers Dis. 2011 ; 26 (2). 299-313
161. Schipper HM, Bennett DA, Liberman A, et al. Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol Aging. 2006 ; 27 (2). 252-261
162. Roth CL, Elfers CT, Figlewicz DP, et al. Vitamin D deficiency in obese rats exacerbates NAFLD and increases hepatic resistin and toll-like receptor activation. Hepatology. 2012 ; 55 (4). 1103-1111
163. Shih PK, Chen YC, Huang YC, Chang YT, Chen JX, Cheng CM. Pretreatment of vitamin D3 ameliorates lung and muscle injury induced by reperfusion of bilateral femoral vessels in a rat model. J Surg Res. 2011 ; 171 (1). 323-328
164. Oermann E, Bidmon HJ, Witte OW, Zilles K. Effects of 1α,25- didroxyvitamin D3 on the expression of HO-1 and GFAP in glial cells of the photothrombotically lesioned cerebral cortex. J Chem Neuroanat. 2004 ; 28 (4). 225-238
165. Shimohama S, Tanino H, Kawakami N, et al. Activation of NADPH oxidase in Alzheimer's disease brains. Biochem Biophys Res Commun. 2000 ; 273 (1). 5-9
166. Jana A, Pahan K. Fibrillar amyloid-beta-activated human astroglia kill primary human neurons via neutral sphingomyelinase: implications for Alzheimer's disease. J Neurosci. 2010 ; 30 (38). 12676-12689
167. Abramov AY, Canevari L, Duchen MR. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci. 2004 ; 24 (2). 565-575
168. Bruce-Keller AJ, Gupta S, Parrino TE, et al. NOX activity is increased in mild cognitive impairment. Antioxid Redox Signal. 2010 ; 12 (12). 1371-1382
169. Ansari MA, Scheff SW. NADPH-oxidase activation and cognition in Alzheimer disease progression. Free Radic Biol Med. 2011 ; 51 (1). 171-178
170. Choi SH, Aid S, Kim HW, Jackson SH, Bosetti F. Inhibition of NADPH
171. Hashizume K, Suzuki S, Ichikawa K, Takeda T, Kobayashi M. Effect of active vitamin D3 on the levels of NADPH-dependent cytosolic 3,5,3'-triiodo-L-thyronine-binding protein. Biochem Biophys Res Commun. 1991 ; 177 (1). 388-394
172. Stio M, Lunghi B, Iantomasi T, Vincenzini MT, Treves C. Effect of vitamin D deficiency and 1,25-dihydroxyvitamin D3 on rat heart metabolism. J Mol Cell Cardiol. 1994 ; 26 (11). 1421-1428
173. Bachelet M, Bader C, Merlot AM, Laborde K, Snarska J, Ulmann A. Cellular utilization of cytosolic NADPH in kidney and liver cells from rats fed a normal or a vitamin D-deficient diet. Cell Biochem Funct. 1983 ; 1 (1). 25-29
174. Husain K, Ferder L, Mizobuchi M, Finch J, Slatopolsky E. Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Am J Nephrol. 2009 ; 29 (5). 465-472
175. Bell NH, Shaw S, Turner RT. Evidence that 1,25-dihydroxyvitamin D3 inhibits the hepatic production of 25-hydroxyvitamin D in man. J Clin Invest. 1984 ; 74 (4). 1540-1544
176. Luong KV, Nguyen LT. Coexisting hyperparathyroidism and primary hyperparathyroidism with vitamin D-deficient osteomalacia in a Vietnamese immigrant. Endocr Pract. 1996 ; 2 (4). 250-254